Cystoscopy with Hydrodistension: Definition and Clinical Benefits
Cystoscopy with hydrodistension is a procedure where the bladder is filled with fluid under controlled pressure during cystoscopic examination, serving both as a diagnostic tool to identify Hunner lesions and assess bladder capacity, and as a therapeutic intervention that provides temporary symptom relief in approximately 50-70% of interstitial cystitis/bladder pain syndrome (IC/BPS) patients.
What It Is
Cystoscopy with hydrodistension involves:
- Visual examination of the bladder interior using a cystoscope
- Bladder distension by filling with sterile fluid under pressure (typically 40-80 cmH₂O)
- Duration ranging from 2 minutes to several hours, though standard protocols use shorter durations (< 15 minutes)
- Can be performed under general, spinal, or local anesthesia 1
The procedure reveals characteristic findings including:
- Hunner lesions (the only definitive cystoscopic finding diagnostic for IC/BPS)
- Glomerulations (petechial hemorrhages) that appear after distension
- Bladder capacity measurement under anesthesia
- Mucosal abnormalities not visible before distension 1, 2
How It Helps Patients
Diagnostic Benefits
Cystoscopy should be performed in patients suspected of having Hunner lesions, as it remains the only reliable way to diagnose their presence 1. This is critical because:
- Hunner lesion IC represents a distinct subtype requiring specific treatment (fulguration/ablation)
- Early diagnosis allows targeted therapy without requiring patients to fail other treatments first 1
- Excludes bladder cancer, stones, and other conditions mimicking IC/BPS 1
- Random biopsies during the procedure can identify bladder carcinoma masquerading as IC/BPS (3 out of 55 cases in one study) 3
The procedure also reveals structural bladder changes including urothelial denudation, inflammatory infiltration, stromal edema, and vascular congestion that may not be macroscopically visible before distension 2.
Therapeutic Benefits
Hydrodistension provides temporary symptom relief with the following characteristics:
- Initial efficacy: 53.8-69.2% of patients experience improvement at 3 months post-procedure 3
- Duration of benefit: Effectiveness decreases over time (25% at 6 months, 13.5% at 12 months) 3
- Symptom improvement in responders includes:
- 50% reduction in daytime frequency
- 49% reduction in nocturia
- 68% reduction in bladder pain (VAS scores)
- 48% improvement in IC symptom scores 3
Patients with chronic pelvic pain as the dominant symptom are more likely to benefit from hydrodistension 3. The procedure appears most effective for the "O" (organ-specific) domain of symptoms (92.9% remission rate), followed by urinary ("U") and tenderness ("T") domains (42.9% each) 3.
Clinical Considerations
Pressure and Duration
Recent evidence suggests:
- Low-pressure hydrodistension (40 cmH₂O for 2 minutes) is adequate to induce glomerulations and may offer better discrimination between IC/BPS and controls 2
- Prolonged hydrodistension (30 minutes to 2 hours) in older studies showed 32-67% long-term improvement but carries increased risk of bladder perforation 4
- Standard practice uses shorter durations (< 15 minutes) to balance efficacy with safety 4
Subtype Implications
Patients with more severe bladder hemorrhage (multiple/diffuse punctate hemorrhage) have smaller baseline bladder capacity and earlier symptom recurrence (at 3 months vs. 6 months for those with focal hemorrhage only) 5. This finding helps predict treatment durability and plan follow-up intervals.
Important Caveats
- Not a first-line treatment: The 2022 AUA guidelines emphasize that initial treatment should typically be nonsurgical except for patients with Hunner lesions 1
- Temporary relief: Most patients experience symptom recurrence requiring repeat procedures or alternative therapies
- Risk of complications: Including bladder perforation, particularly with prolonged high-pressure distension 4
- Patient selection matters: Those with predominantly pelvic pain benefit more than those with primarily urinary frequency 3
The procedure serves dual diagnostic and therapeutic roles, with its greatest value in identifying the Hunner lesion subtype that requires specific ablative treatment and in providing temporary relief while other therapies are initiated 1, 6, 3.